Literature DB >> 23715574

Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.

Philippe Bahadoran1, Maryline Allegra, Florence Le Duff, Elodie Long-Mira, Paul Hofman, Damien Giacchero, Thierry Passeron, Jean-Philippe Lacour, Robert Ballotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23715574     DOI： 10.1200/JCO.2012.46.1061

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  21 in total

Review 1.  Biology and treatment of BRAF mutant metastatic melanoma.

Authors:  Benjamin Y Kong; Matteo S Carlino; Alexander M Menzies
Journal:  Melanoma Manag       Date:  2016-02-12

2.  Management of 'pan-negative' melanoma: current and emerging strategies.

Authors:  Douglas B Johnson; Chengwei Peng; Igor Puzanov
Journal:  Melanoma Manag       Date:  2014-12-04

3.  Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma.

Authors:  Yang Yang; Yi Meng; Hang Zhang; Xiaoyan Shen; Rutian Li; Lixia Yu; Baorui Liu; Lifeng Wang
Journal:  Oncol Lett       Date:  2017-12-19       Impact factor: 2.967

4.  Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Authors:  Douglas B Johnson; Kimberly H Dahlman; Jared Knol; Jill Gilbert; Igor Puzanov; Julie Means-Powell; Justin M Balko; Christine M Lovly; Barbara A Murphy; Laura W Goff; Vandana G Abramson; Marta A Crispens; Ingrid A Mayer; Jordan D Berlin; Leora Horn; Vicki L Keedy; Nishitha M Reddy; Carlos L Arteaga; Jeffrey A Sosman; William Pao
Journal:  Oncologist       Date:  2014-05-05

5.  Integrative molecular profiling of routine clinical prostate cancer specimens.

Authors:  C S Grasso; A K Cani; D H Hovelson; M J Quist; N J Douville; V Yadati; A M Amin; P S Nelson; B L Betz; C-J Liu; K E Knudsen; K A Cooney; F Y Feng; A S McDaniel; S A Tomlins
Journal:  Ann Oncol       Date:  2015-03-03       Impact factor: 32.976

6.  Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.

Authors:  Joshua R Bradish; Justin D Richey; Kristin M Post; Kari Meehan; Joyashree D Sen; Amanda J Malek; Terrence M Katona; Simon Warren; Theodore F Logan; Leslie A Fecher; Liang Cheng
Journal:  Mod Pathol       Date:  2014-11-07       Impact factor: 7.842

Review 7.  Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Authors:  Matthew Dankner; April A N Rose; Shivshankari Rajkumar; Peter M Siegel; Ian R Watson
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

8.  Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.

Authors:  Monika Jurkowska; Aleksandra Gos; Konrad Ptaszyński; Wanda Michej; Andrzej Tysarowski; Renata Zub; Janusz A Siedlecki; Piotr Rutkowski
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Anaplastic Transformation of Papillary Thyroid Carcinoma in a Young Man: A Case Study with Immunohistochemical and BRAF Analysis.

Authors:  Ji Hye Park; Hyeong Ju Kwon; Cheong Soo Park; SoonWon Hong
Journal:  Korean J Pathol       Date:  2014-06-26

10.  [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].

Authors:  O Haase; O Angün; V Grätz; N Lüttmann; A Neumann; D Zillikens; P Terheyden
Journal:  Hautarzt       Date:  2016-08       Impact factor: 0.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.